Vivek Tandon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vivek Tandon has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
Amol Raheja
Department of Neurosurgery, All IndiaIndia Institute of Medical Sciences (AIIMS), New Delhi, 110029, India
19 shared publicationsKanwaljeet Garg
Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
15 shared publicationsRavi Sharma
Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
12 shared publicationsAshish Suri
Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
10 shared publicationsShashwat Mishra
Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
10 shared publicationsVaridh Katiyar
Department of Neurosurgery, All India Institute of Medical Sciences, Nagpur, Maharashtra, India
10 shared publications
Latest Publications
- 23 October 2026
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 155, 112338
Feasibility and preliminary psychological effects of bedside immersive Virtual reality in prolonged bedridden neurosurgical Patients: A Single-Arm pilot study
- 23 October 2026
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 155, 112338
Feasibility and preliminary psychological effects of bedside immersive Virtual reality in prolonged bedridden neurosurgical Patients: A Single-Arm pilot study
- 12 January 2026
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 145, 111850
Clinical assessment of a Near-Infrared spectroscopy device for rapid triage in traumatic brain injury
- 12 January 2026
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 145, 111850
Clinical assessment of a Near-Infrared spectroscopy device for rapid triage in traumatic brain injury
- 15 October 2025
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 142, 111666
The future of neurosurgical training: Role of augmented reality in enhancing skill acquisition and deciphering intracranial complexities
- 15 October 2025
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 142, 111666
The future of neurosurgical training: Role of augmented reality in enhancing skill acquisition and deciphering intracranial complexities
- 6 November 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47  (1) , 1-7
Valproate-induced hyperammonemic encephalopathy in neurosurgical patients: Our experience and systematic literature review
Sodium valproate is used for the management of seizures, status epilepticus, chronic pain syndrome, bipolar, and other affective disorders. Even with an acceptable safety profile, severe idiosyncratic reactions can occur with valproate use. A rare, serious, and life-threatening side effect of valproate is valproate-induced hyperammonemic encephalopathy (VHE). We intend to analyze the clinical presentation, diagnosis, treatment options, and outcome of VHE in neurosurgical patients and review the pertinent literature on this rare sequelae. We retrospectively reviewed patients who developed VHE following valproate use, either for the treatment of epilepsy or for seizure prophylaxis in our centre. We analyzed the demographic details, clinical presentation, diagnosis, management, and outcomes. A total of four patients with a mean age of 26.3 ± 5.1 (range 19 – 32 years). Valproate was prescribed for primary seizure prophylaxis in 2 patients (50%). The commonest etiology for valproate prescription was for brain tumors (3, 75%) followed by drug-refractory epilepsy (DRE) (1, 25%). None of the patients were documented to have urea cycle disorder. The mean daily prescribed dosage of valproate was 1250 ± 559 mg and the mean duration of administration was 13 ± 13.3 months (range 4 months – 36 months). The mean serum NH3 level was 136,5 ± 44.2 µmol/L (range 107 – 212.8) and all patients (4, 100%) had hyperammonemia with a mortality rate of 50% (2 patients). The hyperammonemia was treated by stopping the valproate use (4, 100%) and dialysis (2, 50%). Normalization of ammonia levels led to clinical improvement in 50% (2 patients). Neurological deterioration in the postoperative period is a diagnostic challenge. VHE is a rare and life-threatening sequelae of Valproate-associated Hyperammonemia (VAH) in neurosurgical patients. A high index of suspicion is required due to its ambiguous presentation. Early diagnosis and prompt treatment can change the course of this life-threatening sequelae.
- 6 November 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47  (1) , 1-7
Valproate-induced hyperammonemic encephalopathy in neurosurgical patients: Our experience and systematic literature review
Sodium valproate is used for the management of seizures, status epilepticus, chronic pain syndrome, bipolar, and other affective disorders. Even with an acceptable safety profile, severe idiosyncratic reactions can occur with valproate use. A rare, serious, and life-threatening side effect of valproate is valproate-induced hyperammonemic encephalopathy (VHE). We intend to analyze the clinical presentation, diagnosis, treatment options, and outcome of VHE in neurosurgical patients and review the pertinent literature on this rare sequelae. We retrospectively reviewed patients who developed VHE following valproate use, either for the treatment of epilepsy or for seizure prophylaxis in our centre. We analyzed the demographic details, clinical presentation, diagnosis, management, and outcomes. A total of four patients with a mean age of 26.3 ± 5.1 (range 19 – 32 years). Valproate was prescribed for primary seizure prophylaxis in 2 patients (50%). The commonest etiology for valproate prescription was for brain tumors (3, 75%) followed by drug-refractory epilepsy (DRE) (1, 25%). None of the patients were documented to have urea cycle disorder. The mean daily prescribed dosage of valproate was 1250 ± 559 mg and the mean duration of administration was 13 ± 13.3 months (range 4 months – 36 months). The mean serum NH3 level was 136,5 ± 44.2 µmol/L (range 107 – 212.8) and all patients (4, 100%) had hyperammonemia with a mortality rate of 50% (2 patients). The hyperammonemia was treated by stopping the valproate use (4, 100%) and dialysis (2, 50%). Normalization of ammonia levels led to clinical improvement in 50% (2 patients). Neurological deterioration in the postoperative period is a diagnostic challenge. VHE is a rare and life-threatening sequelae of Valproate-associated Hyperammonemia (VAH) in neurosurgical patients. A high index of suspicion is required due to its ambiguous presentation. Early diagnosis and prompt treatment can change the course of this life-threatening sequelae.
- 31 May 2024
- Published by Elsevier in World Neurosurgery
- Vol. 189, e61-e68
Beyond Traditional Training: Exploring the Benefits of Virtual Reality Simulator in Lumbar Pedicle Screw Insertion - A Randomized Controlled Trial
- 31 May 2024
- Published by Elsevier in World Neurosurgery
- Vol. 189, e61-e68
Beyond Traditional Training: Exploring the Benefits of Virtual Reality Simulator in Lumbar Pedicle Screw Insertion - A Randomized Controlled Trial
- 4 January 2024
- Published by Elsevier in World Neurosurgery
- Vol. 183, e512-e521
Neurosurgery as a Top-Drawer Choice for Residency in India: Reality or Myth?
- 4 January 2024
- Published by Elsevier in World Neurosurgery
- Vol. 183, e512-e521
Neurosurgery as a Top-Drawer Choice for Residency in India: Reality or Myth?
- 1 January 2024
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Neurosurgical Focus
- Vol. 56  (1) , E13
Innovations in craniovertebral junction training: harnessing the power of mixed reality and head-mounted displays
OBJECTIVE: The objective of this study was to analyze the potential and convenience of using mixed reality as a teaching tool for craniovertebral junction (CVJ) anomaly pathoanatomy. METHODS: CT and CT angiography images of 2 patients with CVJ anomalies were used to construct mixed reality models in the HoloMedicine application on the HoloLens 2 headset, resulting in four viewing stations. Twenty-two participants were randomly allocated into two groups, with each participant rotating through all stations for 90 seconds, each in a different order based on their group. At every station, objective questions evaluating the understanding of CVJ pathoanatomy were answered. At the end, subjective opinion on the user experience of mixed reality was provided using a 5-point Likert scale. The objective performance of the two viewing modes was compared, and a correlation between performance and participant experience was sought. Subjective feedback was compiled and correlated with experience. RESULTS: In both groups, there was a significant improvement in median (interquartile range [IQR]) objective performance with mixed reality compared with DICOM: 1) group A: case 1, median 6 (IQR 6–7) versus 5 (IQR 3–6), p = 0.009; case 2, median 6 (IQR 6–7) versus 5 (IQR 3–6), p = 0.02; 2) group B: case 1, median 6 (IQR 5–7) versus 4 (IQR 2–5), p = 0.04; case 2, median 6 (IQR 6–7) versus 5 (IQR 3–7), p = 0.03. There was significantly higher improvement in less experienced participants in both groups for both cases: 1) group A: case 1, r = −0.8665, p = 0.0005; case 2, r = −0.8002, p = 0.03; 2) group B: case 1, r = −0.6977, p = 0.01; case 2, r = −0.7417, p = 0.009. Subjectively, mixed reality was easy to use, with less disorientation due to the visible background, and it was believed to be a useful teaching tool. CONCLUSIONS: Mixed reality is an effective teaching tool for CVJ pathoanatomy, particularly for young neurosurgeons and trainees. The versatility of mixed reality and the intuitiveness of the user experience offer many potential applications, including training, intraoperative guidance, patient counseling, and individualized medicine; consequently, mixed reality has the potential to transform neurosurgery.
- 1 January 2024
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Neurosurgical Focus
- Vol. 56  (1) , E13
Innovations in craniovertebral junction training: harnessing the power of mixed reality and head-mounted displays
OBJECTIVE: The objective of this study was to analyze the potential and convenience of using mixed reality as a teaching tool for craniovertebral junction (CVJ) anomaly pathoanatomy. METHODS: CT and CT angiography images of 2 patients with CVJ anomalies were used to construct mixed reality models in the HoloMedicine application on the HoloLens 2 headset, resulting in four viewing stations. Twenty-two participants were randomly allocated into two groups, with each participant rotating through all stations for 90 seconds, each in a different order based on their group. At every station, objective questions evaluating the understanding of CVJ pathoanatomy were answered. At the end, subjective opinion on the user experience of mixed reality was provided using a 5-point Likert scale. The objective performance of the two viewing modes was compared, and a correlation between performance and participant experience was sought. Subjective feedback was compiled and correlated with experience. RESULTS: In both groups, there was a significant improvement in median (interquartile range [IQR]) objective performance with mixed reality compared with DICOM: 1) group A: case 1, median 6 (IQR 6–7) versus 5 (IQR 3–6), p = 0.009; case 2, median 6 (IQR 6–7) versus 5 (IQR 3–6), p = 0.02; 2) group B: case 1, median 6 (IQR 5–7) versus 4 (IQR 2–5), p = 0.04; case 2, median 6 (IQR 6–7) versus 5 (IQR 3–7), p = 0.03. There was significantly higher improvement in less experienced participants in both groups for both cases: 1) group A: case 1, r = −0.8665, p = 0.0005; case 2, r = −0.8002, p = 0.03; 2) group B: case 1, r = −0.6977, p = 0.01; case 2, r = −0.7417, p = 0.009. Subjectively, mixed reality was easy to use, with less disorientation due to the visible background, and it was believed to be a useful teaching tool. CONCLUSIONS: Mixed reality is an effective teaching tool for CVJ pathoanatomy, particularly for young neurosurgeons and trainees. The versatility of mixed reality and the intuitiveness of the user experience offer many potential applications, including training, intraoperative guidance, patient counseling, and individualized medicine; consequently, mixed reality has the potential to transform neurosurgery.
- 9 May 2023
- Published by Springer Nature in Child's Nervous System
- Vol. 39  (8) , 2019-2026
Spinal atypical teratoid rhabdoid tumor-narrative review and report of a rare case managed with multimodality approach
Background Spinal atypical teratoid rhabdoid tumor (AT/RT) is an extremely rare tumor and represents less than 2% of all AT/RTs. Methods Available medical literature on spinal AT/RT in English was retrieved from PubMed and comprehensively reviewed. Clinical presentation, diagnosis, management, prognosis, and outcome in patients with spinal AT/RT have been elucidated by citing a case of extradural AT/RT of the cervicodorsal spine. Results The age at presentation is usually less than 3 years. The most common site is the cervicodorsal spine. The most frequent tumor location is intradural extramedullary. A contrast-enhanced magnetic resonance imaging (MRI) of the entire neuraxis is the imaging modality of choice. The incidence of leptomeningeal dissemination is high (15–30%). Histopathological examination shows an admixture of primitive neuroectodermal, mesenchymal, and epithelial elements along with rhabdoid cells. Loss of SMARCB1/INI1 is considered pathognomonic of AT/RT. Maximal safe resection of tumor is the initial management of choice. Thereafter focal radiotherapy for localized tumor or craniospinal irradiation for leptomeningeal dissemination should be considered. Post-operative intensive polychemotherapy including intrathecal and high-dose chemotherapy (with autologous stem cell rescue) is usually considered to optimize survival. Typically, the time to recurrence and overall survival are less than 6 and 12 months, respectively. However, with judicious multimodality management long-term survivors are increasingly being recognized. The illustrative patient was a 18-month-old girl diagnosed with extradural AT/RT of the cervicodorsal spine (C3-D1), who was managed with maximal safe resection of tumor, multiagent chemotherapy (ICE-ifosfamide, carboplatin, etoposide) and focal RT to the tumor bed—50.4 Gy/28 fractions/5.5 weeks. At the last follow-up visit, 30 months after surgery, she had complete clinicoradiological response. Conclusion Multimodal treatment comprising maximal safe resection of tumor, multiagent chemotherapy (ICE), and focal RT can lead to successful outcome in patients with localized spinal AT/RT, under the age of 3 years.
- 9 May 2023
- Published by Springer Nature in Child's Nervous System
- Vol. 39  (8) , 2019-2026
Spinal atypical teratoid rhabdoid tumor-narrative review and report of a rare case managed with multimodality approach
Background Spinal atypical teratoid rhabdoid tumor (AT/RT) is an extremely rare tumor and represents less than 2% of all AT/RTs. Methods Available medical literature on spinal AT/RT in English was retrieved from PubMed and comprehensively reviewed. Clinical presentation, diagnosis, management, prognosis, and outcome in patients with spinal AT/RT have been elucidated by citing a case of extradural AT/RT of the cervicodorsal spine. Results The age at presentation is usually less than 3 years. The most common site is the cervicodorsal spine. The most frequent tumor location is intradural extramedullary. A contrast-enhanced magnetic resonance imaging (MRI) of the entire neuraxis is the imaging modality of choice. The incidence of leptomeningeal dissemination is high (15–30%). Histopathological examination shows an admixture of primitive neuroectodermal, mesenchymal, and epithelial elements along with rhabdoid cells. Loss of SMARCB1/INI1 is considered pathognomonic of AT/RT. Maximal safe resection of tumor is the initial management of choice. Thereafter focal radiotherapy for localized tumor or craniospinal irradiation for leptomeningeal dissemination should be considered. Post-operative intensive polychemotherapy including intrathecal and high-dose chemotherapy (with autologous stem cell rescue) is usually considered to optimize survival. Typically, the time to recurrence and overall survival are less than 6 and 12 months, respectively. However, with judicious multimodality management long-term survivors are increasingly being recognized. The illustrative patient was a 18-month-old girl diagnosed with extradural AT/RT of the cervicodorsal spine (C3-D1), who was managed with maximal safe resection of tumor, multiagent chemotherapy (ICE-ifosfamide, carboplatin, etoposide) and focal RT to the tumor bed—50.4 Gy/28 fractions/5.5 weeks. At the last follow-up visit, 30 months after surgery, she had complete clinicoradiological response. Conclusion Multimodal treatment comprising maximal safe resection of tumor, multiagent chemotherapy (ICE), and focal RT can lead to successful outcome in patients with localized spinal AT/RT, under the age of 3 years.
- 7 March 2023
- Published by Elsevier in World Neurosurgery
- Vol. 173, e683-e698
SimSpine: A Cost-Effective Spinal Endoscopy Training Prototype for Neurosurgical Residents Skills Training
- 7 March 2023
- Published by Elsevier in World Neurosurgery
- Vol. 173, e683-e698
SimSpine: A Cost-Effective Spinal Endoscopy Training Prototype for Neurosurgical Residents Skills Training
- 10 August 2022
- Published by Elsevier in World Neurosurgery
- Vol. 167, e333-e343
A High-Fidelity Agar-Based Phantom for Ultrasonography-Guided Brain Biopsy Simulation: A Novel Training Prototype with Visual Feedback
- 10 August 2022
- Published by Elsevier in World Neurosurgery
- Vol. 167, e333-e343
A High-Fidelity Agar-Based Phantom for Ultrasonography-Guided Brain Biopsy Simulation: A Novel Training Prototype with Visual Feedback